Whan Kim - Academia.edu (original) (raw)

Papers by Whan Kim

Journal of the American Academy of Dermatology, 2016

European journal of dermatology : EJD, Jan 30, 2015

Administrative databases provide valuable patient data and are used to conduct population-based s... more Administrative databases provide valuable patient data and are used to conduct population-based studies. However, no studies have been conducted to validate the codes for dermatological conditions. To evaluate the validity of ICD 9 code 706 for acne. This was a retrospective chart review of patients seen in dermatology clinics at Sunnybrook Health Sciences Centre between March 1 and May 31, 2013. The billing code for a clinic visit was compared to the diagnosis documented in the medical chart. There were 4,248 participants; 201 with an ICD-9 code of acne. This code had a PPV and sensitivity with 95% confidence intervals (CI) of 84.58% (78.67-89.13%) and 86.29% (80.51-90.62%), respectively. The specificity was 99.20% (98.86-99.45%). We showed that ICD-9 code 706 can be used to accurately identify patients with acne in a dermatology setting. This information can be applied to future epidemiologic studies.

Journal of cutaneous medicine and surgery, Jan 15, 2015

Lupus miliaris disseminatus faciei (LMDF) is a chronic, granulomatous inflammatory disorder, comm... more Lupus miliaris disseminatus faciei (LMDF) is a chronic, granulomatous inflammatory disorder, commonly localized to the face. To present an unusual manifestation of LMDF and review the literature. We document a 41-year-old woman with LMDF with isolated axillary involvement. A literature review was conducted using Pubmed, Medline, Embase, and Google Scholar for similar cases using search terms lupus miliaris disseminatus faciei, LMDF, acne agminata, and acnitis. Extrafacial LMDF without concomitant facial involvement is rare; there has been only 1 other report of LMDF with exclusive axillary involvement to date. In addition, we report the successful use of doxycycline monohydrate combined with topical tacrolimus in the treatment of LMDF. Physicians should note that LMDF can occur in body sites other than the face and should be aware of the available treatment options to manage this condition.

Journal of cutaneous medicine and surgery, Jan 28, 2015

Despite the high burden of disease associated with hidradenitis suppurativa (HS), epidemiologic d... more Despite the high burden of disease associated with hidradenitis suppurativa (HS), epidemiologic data are scarce. The objective was to review demographic features and clinical findings in 80 HS patients from 2 referral centres in Ontario, Canada, from October 2013 to September 2014, and to assess for factors that are associated with more advanced disease. Multicentre cross-sectional study. The data on demographic and clinical features were obtained by questionnaires and chart review. Of a total of 80 patients (67.5% females), percentages of patients in Hurley stages I, II, and III were 15.4%, 55.8%, and 28.9%, respectively. Most patients were not diagnosed for more than 1 year (70.1%). Patients with more severe disease were more likely to be females and to have a greater number of lesions and were less likely to be diagnosed initially by a dermatologist. This study documents the common demographic and clinical features of HS to optimize resource allocation and patient outcomes.

Journal of the American Academy of Dermatology, 2015

Safety profiles of biologics for treatment of psoriasis are limited to data from randomized contr... more Safety profiles of biologics for treatment of psoriasis are limited to data from randomized controlled trials. There is a need for comparative safety reports of biologics based on data from clinical practice. We sought to estimate and compare the incidence of adverse events (AEs) leading to withdrawal of biologics (etanercept, infliximab, adalimumab, and ustekinumab) in the treatment of psoriasis. We conducted a multicenter retrospective chart review from September 2005 to September 2014. Incidence proportion and rate of AEs leading to withdrawal by biologic agent and AE were calculated. For 545 treatments administered in 398 patients, 22 (4.04%) AEs were associated with withdrawal, for a rate of 1.97/100 patient-years (95% confidence interval [CI] 1.32-2.94). Common AEs were injection-/infusion-site reactions (0.55%, 0.92%, 0%, and 0% for etanercept, infliximab, adalimumab, and ustekinumab, respectively); infections (0%, 0.18%, 0.55%, 0.18%); and malignancies (0.18%, 0.18%, 0%, 0.37%). Possible incompleteness of chart details and small study population limit the conclusiveness of findings. Biologic agents for treatment of psoriasis are safe; AEs associated with withdrawal occurred in 4% of all administered biologic therapies. It does not appear that real-world patients encounter more AEs with biologics than patients in clinical trials.

The international journal of lower extremity wounds, Jan 7, 2014

Pretibial myxedema (PM) is a rare autoimmune manifestation of Graves' disease, which commonly... more Pretibial myxedema (PM) is a rare autoimmune manifestation of Graves' disease, which commonly presents as diffuse, nonpitting edema of shins and less often as plaques, nodules, or elephantiasis lesions mimicking lymphedema. We present a 57-year-old woman with 12-month history of PM, which occurred a year after treatment of Graves' disease and improved with topical corticosteroids, support stockings, and intralesional steroid injections until recurrence with local erythema and woody edema. A literature review was undertaken of the evidence-based treatment modalities for symptomatic PM: although commonly asymptomatic and self-limited, severe cases of PM may be treated with topical corticosteroid, compressive therapy, and intralesional corticosteroid injections.

Journal of cutaneous medicine and surgery, Jan 13, 2015

The gtring presence of dermatology platforms on Facebook has been acknowledged; however, little i... more The gtring presence of dermatology platforms on Facebook has been acknowledged; however, little is known about the extent to which different types of content influence the level of engagement with online users. To assess the level of public engagement with different types of content posted on Facebook pages devoted to dermatology. A search on Facebook identified existing pages for dermatology academic journals, professional societies, and patient-centered groups. Then the engagement rate was calculated for each content type published on the selected pages. The median engagement rates were 63.8% for educational posts, 41.3% for interactive posts, 27.4% for news articles, 11.8% for academic articles, and 9.3% for others. Educational posts engaged with online users the most effectively. The level of engagement is a key determinant of knowledge dissemination via online tools, and the type of content may influence the level of engagement.

American journal of clinical dermatology, 2015

Hidradenitis suppurativa (HS) is a chronic relapsing condition with a clinical picture that inclu... more Hidradenitis suppurativa (HS) is a chronic relapsing condition with a clinical picture that includes solitary nodules; diffuse, painful abscesses; malodorous drainage; sinus tract formation; and scarring. Treatment options are often unsatisfactory. The adverse effects of this disease on quality of life (QoL) is not extensively studied, especially in the Canadian population. The objectives of this study were to (1) identify the impairment of QoL in patients with HS and the aspects that are most affected, and (2) assess the correlation between disease severity (based on Hurley's staging) and QoL impairment. This prospective case series studied 55 patients (38 females and 17 males) from community dermatology clinics in Ontario. All patients filled out the questionnaires for QoL data using the Dermatology Life Quality Index (DLQI) and the Short Form 36 Version 2 (SF-36v2) health survey, either in the clinic or over the telephone. The mean DLQI score was 10 ± 8.8, indicating a modera...

The international journal of lower extremity wounds, Jan 17, 2015

Epidermolysis bullosa (EB) pruriginosa is a rare clinical subtype of dystrophic epidermolysis bul... more Epidermolysis bullosa (EB) pruriginosa is a rare clinical subtype of dystrophic epidermolysis bullosa (DEB) that is characterized by intense pruritus resulting in hypertrophic, lichenified, prurigo-like plaques and nodules secondary to scratching. The variability in the age of onset, rarity of intact bullae, histologic ambiguities, and close resemblance to other conditions such as acquired inflammatory dermatoses may make diagnosis difficult for this unusual condition, for which fewer than 100 cases have been documented. In this report, we describe 3 cases of EB pruriginosa and review the current literature.

American journal of clinical dermatology, Jan 18, 2015

Epidermolysis bullosa pruriginosa (EBP) is a clinical variant of dystrophic epidermolysis bullosa... more Epidermolysis bullosa pruriginosa (EBP) is a clinical variant of dystrophic epidermolysis bullosa (DEB), characterized by intense pruritus and hypertrophic, lichenified, prurigo-like papules, plaques, and nodules secondary to scratching. These clinical findings have been attributed to various mutations in the COL7A1 gene. Previous reports have yielded inconsistent findings regarding a possible genotype-phenotype relationship in EBP. Our aim was to conduct a systematic review aimed at assessing the genotype-phenotype correlation in EBP. A systematic review was conducted using PubMed, Medline, EMBASE, and Cochrane databases for all reports of mutation-verified EBP, published from 1946 to September 2014. Statistical comparison of clinical findings between mutation types was performed using logistic regression analysis. The review included a total of 28 articles with 74 individuals, which consisted of level 4 non-controlled case series (grade C) and level 5 case reports (grade D). Previ...